Company Research Report: Indapta Therapeutics, Inc.

Company Overview

• Name: Indapta Therapeutics, Inc.

• Mission: Harnessing the natural power of the immune system to fight hematologic and solid cancers.

• Founding Date: No information is available.

• Founders: No information is available.

• Key People:

• Mark W. Frohlich, M.D., Chief Executive Officer

• Guy DiPierro, Chief Operating Officer and Co-Founder

• Robert Sikorski, MD, Acting Chief Medical Officer

• Austin Bigley, PH.D., VP of Research

• Stefanie Mandl-Cashman, Chief Scientific Officer

• Linda Barnes, Head of Regulatory & Quality

• Headquarters: Houston, TX, and Seattle, WA

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Developing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy aimed to treat multiple types of cancer and expanding into treatments for autoimmune diseases.

Products

1. G-NK Cell Therapy

• Description: Indapta’s universal, allogeneic NK cell therapy platform involves a potent subset of naturally occurring NK cells known as g-NK cells, deficient in the FceR1γ protein.

• Key Features:

• Derived from healthy donors.

• Combined with FDA-approved tumor-targeting antibodies.

• Higher antibody-dependent cell-mediated cytotoxicity (ADCC).

• Increased cytokine secretion and levels of cytolytic enzymes.

• Epigenetic changes include down-modulation of the FceR1γ chain.

2. IDP-023

• Description: A g-NK cell therapy product aimed at treating hematologic cancers and autoimmune diseases.

• Key Features:

• Multiple mechanisms, including high robust antibody-dependent cell-mediated cytotoxicity.

• Targets HLA-E expressing cells.

• Inherent anti-viral activity.

• Used in combination with monoclonal antibodies such as rituximab and daratumumab.

Recent Developments

• New Products Launched:

• Initiation of treatment for the first patients with IDP-023 in Phase 1 trial for multiple myeloma and Non-Hodgkin’s lymphoma.

• New Features:

• Enhanced manufacturing process aimed at increasing yields in GMP production runs.

• Recent Partnerships:

• Collaborations with Stanford University and UCSF for clinical trials.

• FDA Clearance and Designations:

• FDA clearance of IND for Phase 1 trial of IDP-023 for progressive multiple sclerosis.

• FDA Fast Track designation for IDP-023 targeting Non-Hodgkin’s Lymphoma and Myeloma.

• Publications and Presentations:

• Presentation on g-NK cells at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference.

• Grants and Awards:

• Awarded $4.5 million by CPRIT to support clinical development of IDP-023.

Conclusion

Indapta Therapeutics is at the forefront of developing next-generation cell therapies for cancer and autoimmune diseases. The company's commitment to utilizing naturally occurring NK cells showcases their innovative approach to improving treatment efficacy and accessibility. Although still in the clinical stages, recent advancements, collaborations, and FDA recognitions underscore Indapta Therapeutics' progress and potential impact in the biotechnological landscape.